Converge Bio, an innovative startup focused on AI-driven drug discovery, has successfully raised $25 million through a Series A funding round. This investment was spearheaded by Bessemer Venture Partners and received strong support from prominent executives associated with major companies like Meta, OpenAI, and Wiz. The funding marks a significant milestone for Converge Bio as it aims to revolutionize the pharmaceutical industry using artificial intelligence to expedite the drug development process, enhancing efficiency and effectiveness in bringing new treatments to market.